skip to content


Amphion partner releases positive clinical results

05 October 2017 07:35

Amphion partner company Motif Bio has announced positive topline results for iclaprim in the REVIVE-2 phase 3 study.

Amphion - which owns 14.1% of Motif Bio's issued share capital - said iclaprim met the primary endpoint and was well tolerated in the study.

It said a new drug application was expected in the first quarter of 2018.

Amphion Innovations chief executive Richard Morgan said: 'We are pleased that Motif Bio's lead antibiotic, iclaprim, has now successfully completed both of its Phase III trials.

'Yesterday, Motif Bio announced the topline data for REVIVE-2, the second of the two trials, which showed that iclaprim achieved the primary endpoint of non-inferiority compared to vancomycin, the current standard of care, at the early time point (ETP), and also achieved non-inferiority at the test of cure endpoint, 7 to 14 days after study drug discontinuation.

'Combined with the positive topline data for REVIVE-1, as announced 18 April 2017, Motif Bio is on track to submit a New Drug Application to the US FDA for iclaprim in the first quarter of 2018.

'Amphion owns 14.1% of Motif Bio, and we continue to believe that Motif Bio is not fully valued compared to other comparable antibiotic companies at the same stage of development.'

Story provided by

Related Company: AMP

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.